- Zacks
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
